Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Carde

Showing results (121-130 of 129) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 129 results.
Bone Marrow Transplantation|June 19, 1998
VIP (etoposide, ifosfamide and cisplatinum) as a salvage intensification program in relapsed or refractory Hodgkin's diseaseV Ribrag, F Nasr, J H Bouhris, et al.
European Journal of Cancer (Oxford, England : 1990)|February 14, 2004
Long-term efficacy of the CHVmP/BV regimen used for aggressive non-Hodgkin's lymphoma in three randomised EORTC trialsE C Moser, E M Noordijk, M van Glabbeke, et al.
Blood|January 15, 1998
The tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (Goralatide) protects from doxorubicin-induced toxicity: improvement in mice survival and protection of bone marrow stem cells and progenitorsA Massé, L H Ramirez, G Bindoula, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 15, 2009
JC human polyomavirus is associated to chromosomal instability in peripheral blood lymphocytes of Hodgkin's lymphoma patients and poor clinical outcomeR M'kacher, L Andreoletti, S Flamant, et al.
Leukemia & Lymphoma|August 1, 1997
Mantle cell lymphomas: characteristics, natural history and prognostic factors of 45 casesD Decaudin, J Bosq, J N Munck, et al.
Oncogene|September 13, 2003
Multiple molecular mechanisms contribute to radiation sensitivity in mantle cell lymphomaR M'kacher, A Bennaceur, F Farace, et al.
Bone Marrow Transplantation|November 29, 2016
First-line escalated BEACOPP does not hinder stem cell collection and transplantation strategy in patients with relapsed/refractory Hodgkin's lymphomaD Ghez, C Fortpied, N Mounier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 16, 2014
ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥ 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trialN Mounier, P Brice, S Bologna, et al.
Radiation Protection Dosimetry|October 3, 2014
Telomere shortening: a new prognostic factor for cardiovascular disease post-radiation exposureR M'kacher, T Girinsky, B Colicchio, et al.
Pageof 13

Showing results (121-130 of 129) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 129 results.
Bone Marrow Transplantation|June 19, 1998
VIP (etoposide, ifosfamide and cisplatinum) as a salvage intensification program in relapsed or refractory Hodgkin's diseaseV Ribrag, F Nasr, J H Bouhris, et al.
European Journal of Cancer (Oxford, England : 1990)|February 14, 2004
Long-term efficacy of the CHVmP/BV regimen used for aggressive non-Hodgkin's lymphoma in three randomised EORTC trialsE C Moser, E M Noordijk, M van Glabbeke, et al.
Blood|January 15, 1998
The tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (Goralatide) protects from doxorubicin-induced toxicity: improvement in mice survival and protection of bone marrow stem cells and progenitorsA Massé, L H Ramirez, G Bindoula, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 15, 2009
JC human polyomavirus is associated to chromosomal instability in peripheral blood lymphocytes of Hodgkin's lymphoma patients and poor clinical outcomeR M'kacher, L Andreoletti, S Flamant, et al.
Leukemia & Lymphoma|August 1, 1997
Mantle cell lymphomas: characteristics, natural history and prognostic factors of 45 casesD Decaudin, J Bosq, J N Munck, et al.
Oncogene|September 13, 2003
Multiple molecular mechanisms contribute to radiation sensitivity in mantle cell lymphomaR M'kacher, A Bennaceur, F Farace, et al.
Bone Marrow Transplantation|November 29, 2016
First-line escalated BEACOPP does not hinder stem cell collection and transplantation strategy in patients with relapsed/refractory Hodgkin's lymphomaD Ghez, C Fortpied, N Mounier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 16, 2014
ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥ 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trialN Mounier, P Brice, S Bologna, et al.
Radiation Protection Dosimetry|October 3, 2014
Telomere shortening: a new prognostic factor for cardiovascular disease post-radiation exposureR M'kacher, T Girinsky, B Colicchio, et al.
Pageof 13